In a recent article published in Science , researchers reviewed clinical studies on the advantages of glucagon-like peptide-1 (GLP-1) medicines beyond glycemic and weight control. Study: The benefits of GLP-1 drugs beyond obesity . Image Credit: KK Stock/Shutterstock.
com Introduction GLP-1 medications, used to treat primarily obesity and diabetes, reduce inflammation indirectly through weight reduction, neuronal GLP-1 receptor (GLP-1R) activation, and directly through T cell activation. Glucagon receptors, found in hepatocytes and renal cells, may provide further advantages, perhaps lowering the incidence of metabolic liver diseases and diabetic kidney disease. They are under investigation for neurological and psychiatric illnesses, and their efficacy in clinical trials could broaden the range of therapeutic indications that benefit from GLP-1 therapy.
About the article In the present article, researchers discuss potential non-weight-lowering applications of GLP-1 drugs. Cardiovascular, hepatic, and renal benefits of GLP-1 medicines GLP-1 medicines, mostly acylated peptides like semaglutide and liraglutide, have pleiotropic effects beyond weight and glycemic management, including renal and heart disease prevention. Their actions in lowering systemic inflammation have important implications for future clinical applications and medication development.
Semaglutide lowers renal diseases and cardiovascular mortality by 24% among type 2 diabetes patients . In animal models of renal.